

Rowan T Chlebowski

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4412699/rowan-t-chlebowski-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

363
papers

31,129
citations

76
h-index

171
g-index

381
ext. papers

35,221
ext. citations

8.2
avg, IF

6.56
L-index

#	Paper	IF	Citations
363	Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2004 , 291, 1701-12	27.4	3160
362	Calcium plus vitamin D supplementation and the risk of fractures. <i>New England Journal of Medicine</i> , 2006 , 354, 669-83	59.2	1366
361	Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. <i>JAMA - Journal of the American Medical Association</i> , 2003 , 289, 3243-53	27.4	1294
360	American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. <i>Journal of Clinical Oncology</i> , 2003 , 21, 4042-57	2.2	812
359	Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 310, 1353-68	27.4	811
358	Calcium plus vitamin D supplementation and the risk of colorectal cancer. <i>New England Journal of Medicine</i> , 2006 , 354, 684-96	59.2	772
357	Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 655-66	27.4	738
356	The decrease in breast-cancer incidence in 2003 in the United States. <i>New England Journal of Medicine</i> , 2007 , 356, 1670-4	59.2	738
355	Exemestane for breast-cancer prevention in postmenopausal women. <i>New England Journal of Medicine</i> , 2011 , 364, 2381-91	59.2	705
354	Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 1767-76	9.7	633
353	Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 629-42	27.4	553
352	Estrogen plus progestin and colorectal cancer in postmenopausal women. <i>New England Journal of Medicine</i> , 2004 , 350, 991-1004	59.2	496
351	Ethnicity and breast cancer: factors influencing differences in incidence and outcome. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 439-48	9.7	471
350	Weight loss in breast cancer patient management. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1128-43	2.2	457
349	A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). <i>Nature Genetics</i> , 2009 , 41, 579-84	36.3	452
348	Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 1647-57	27.4	410
347	Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). <i>Cancer Causes and Control</i> , 2002 , 13, 741-51	2.8	393

346	Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. <i>JAMA - Journal of the American Medical Association</i> , 2010 , 304, 1684-92	27.4	391
345	Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 1305-14	27.4	381
344	Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4875-82	2.2	376
343	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. <i>American Journal of Human Genetics</i> , 2019 , 104, 21-34	11	363
342	Breast cancer after use of estrogen plus progestin in postmenopausal women. <i>New England Journal of Medicine</i> , 2009 , 360, 573-87	59.2	345
341	Performance of common genetic variants in breast-cancer risk models. <i>New England Journal of Medicine</i> , 2010 , 362, 986-93	59.2	334
340	Calcium plus vitamin D supplementation and the risk of breast cancer. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 1581-91	9.7	332
339	American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. <i>Journal of Clinical Oncology</i> , 2000 , 18, 1378-91	2.2	296
338	Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA Oncology</i> , 2015 , 1, 611-21	13.4	294
337	Meta-analysis of vascular and neoplastic events associated with tamoxifen. <i>Journal of General Internal Medicine</i> , 2003 , 18, 937-47	4	286
336	Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 295, 643-54	27.4	283
335	Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 1036-45	27.4	279
334	Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women's Health Initiative Randomized Trials. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 318, 927-938	27.4	268
333	Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. <i>Lancet Oncology, The</i> , 2012 , 13, 476-86	21.7	262
332	Adherence to endocrine therapy for breast cancer. <i>Oncology</i> , 2006 , 71, 1-9	3.6	256
331	Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. <i>Cancer Research</i> , 2003 , 63, 6096-101	10.1	239
330	American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3235-58	2.2	223
329	Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. <i>Lancet, The</i> , 2009 , 374, 1243-51	40	219

328	Physical activity and survival in postmenopausal women with breast cancer: results from the women's health initiative. <i>Cancer Prevention Research</i> , 2011 , 4, 522-9	3.2	210
327	Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1366-76	9.7	207
326	American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3317-27	2.2	196
325	Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. <i>Maturitas</i> , 2006 , 55, 103-15	5	177
324	American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3328-43	2.2	166
323	Oral bisphosphonate use and breast cancer incidence in postmenopausal women. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3582-90	2.2	162
322	Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 470-7	9.7	160
321	Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1534-43	9.7	160
320	Metformin and breast cancer risk: a meta-analysis and critical literature review. <i>Breast Cancer Research and Treatment</i> , 2012 , 135, 639-46	4.4	156
319	The Women's Health Initiative Dietary Modification trial: overview and baseline characteristics of participants. <i>Annals of Epidemiology</i> , 2003 , 13, S87-97	6.4	155
318	Diabetes, metformin, and breast cancer in postmenopausal women. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2844-52	2.2	151
317	Statin use and breast cancer: prospective results from the Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2006 , 98, 700-7	9.7	146
316	Symptoms potentially influencing weight loss in a cancer population. Correlations with primary site, nutritional status, and chemotherapy administration. <i>Cancer</i> , 1989 , 63, 330-4	6.4	144
315	Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 526-35	9.7	143
314	Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials. <i>JAMA Oncology</i> , 2015 , 1, 296-305	13.4	141
313	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. <i>Endocrine-Related Cancer</i> , 2007 , 14, 169-87	5.7	141
312	Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative. <i>Cancer Prevention Research</i> , 2014 , 7, 42-53	3.2	140
311	American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1939-55	2.2	139

310	Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. <i>Cancer</i> , 1984 , 53, 2701-6	6.4	135
309	Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 454-63	4	134
308	Monitoring dietary change in a low-fat diet intervention study: advantages of using 24-hour dietary recalls vs food records. <i>Journal of the American Dietetic Association</i> , 1996 , 96, 574-9		128
307	Repeated measures of serum glucose and insulin in relation to postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2009 , 125, 2704-10	7.5	120
306	Adherence to endocrine therapy in breast cancer adjuvant and prevention settings. <i>Cancer Prevention Research</i> , 2014 , 7, 378-87	3.2	115
305	Adipokines linking obesity with colorectal cancer risk in postmenopausal women. <i>Cancer Research</i> , 2012 , 72, 3029-37	10.1	114
304	Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. <i>American Journal of Epidemiology</i> , 2008 , 167, 1207-16	3.8	111
303	Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. <i>American Journal of Epidemiology</i> , 2008 , 167, 1407-15	3.8	111
302	Long-term survival following relapse after 5-FU but not CMF adjuvant breast cancer therapy. <i>Breast Cancer Research and Treatment</i> , 1986 , 7, 23-30	4.4	110
301	Changing concepts: Menopausal hormone therapy and breast cancer. <i>Journal of the National Cancer Institute</i> , 2012 , 104, 517-27	9.7	105
300	Predicting risk of breast cancer in postmenopausal women by hormone receptor status. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1695-705	9.7	103
299	Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i> , 2018 , 25, 11-20	2.5	103
298	Alcohol consumption and risk of postmenopausal breast cancer by subtype: the women's health initiative observational study. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1422-31	9.7	101
297	Association of Body Fat and Risk of Breast Cancer in Postmenopausal Women With Normal Body Mass Index: A Secondary Analysis of a Randomized Clinical Trial and Observational Study. <i>JAMA Oncology</i> , 2019 , 5, 155-163	13.4	92
296	Recreational physical activity, body mass index, and survival in women with colorectal cancer. <i>Cancer Causes and Control</i> , 2012 , 23, 1939-48	2.8	90
295	Metabolic abnormalities in the cancer patient. <i>Cancer</i> , 1985 , 55, 225-9	6.4	87
294	Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2020 , 324, 369-380	27.4	85
293	Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. <i>Journal of the National Cancer Institute</i> , 2010 , 102, 1413-21	9.7	84

292	Nutrition and physical activity influence on breast cancer incidence and outcome. <i>Breast</i> , 2013 , 22 Suppl 2, S30-7	3.6	82
291	The effects of a low-fat dietary intervention and tamoxifen adjuvant therapy on the serum estrogen and sex hormone-binding globulin concentrations of postmenopausal breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 1993 , 27, 253-62	4.4	80
290	Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. <i>Breast Cancer Research and Treatment</i> , 2009 , 118, 81-7	4.4	79
289	Influence of nandrolone decanoate on weight loss in advanced non-small cell lung cancer. <i>Cancer</i> , 1986 , 58, 183-6	6.4	78
288	Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2609-18	4	76
287	The effects of tamoxifen and estrogen on brain metabolism in elderly women. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 592-7	9.7	76
286	Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 562-70	9.7	75
285	Estrogen plus progestin and colorectal cancer incidence and mortality. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3983-90	2.2	75
284	Frequency and predictive value of a mammographic recommendation for short-interval follow-up. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 429-36	9.7	74
283	Calcium plus vitamin D supplementation and health outcomes five years after active intervention ended: the Women's Health Initiative. <i>Journal of Women's Health</i> , 2013 , 22, 915-29	3	73
282	Body mass index and waist circumference in relation to lung cancer risk in the Women's Health Initiative. <i>American Journal of Epidemiology</i> , 2008 , 168, 158-69	3.8	73
281	Dietary cadmium exposure and risk of breast, endometrial, and ovarian cancer in the Women's Health Initiative. <i>Environmental Health Perspectives</i> , 2014 , 122, 594-600	8.4	71
280	American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. <i>Journal of Clinical Oncology</i> , 2003 , 21, 2597-9	2.2	70
279	Circulating Adipokines and Inflammatory Markers and Postmenopausal Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	69
278	Significance of altered nutritional status in acquired immune deficiency syndrome (AIDS). <i>Nutrition and Cancer</i> , 1985 , 7, 85-91	2.8	69
277	The effect of calcium plus vitamin D on risk for invasive cancer: results of the Women's Health Initiative (WHI) calcium plus vitamin D randomized clinical trial. <i>Nutrition and Cancer</i> , 2011 , 63, 827-41	2.8	68
276	Influence of stressors on breast cancer incidence in the Women's Health Initiative. <i>Health Psychology</i> , 2009 , 28, 137-46	5	67
275	Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2919-2926	2.2	66

274	Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. <i>American Journal of Clinical Nutrition</i> , 2009 , 90, 162-97		66
273	Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. <i>Cancer</i> , 2008 , 113, 907-15	6.4	66
272	Association between dietary inflammatory potential and breast cancer incidence and death: results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016 , 114, 1277-85	8.7	66
271	Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. <i>Archives of Internal Medicine</i> , 2008 , 168, 370-7; quiz 345		65
270	Statin use and all-cancer survival: prospective results from the Women's Health Initiative. <i>British Journal of Cancer</i> , 2016 , 115, 129-35	8.7	64
269	Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986 , 58, 1867-73	6.4	64
268	Mammographic Density Change With Estrogen and Progestin Therapy and Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	63
267	Association of Normal-Weight Central Obesity With All-Cause and Cause-Specific Mortality Among Postmenopausal Women. <i>JAMA Network Open</i> , 2019 , 2, e197337	10.4	62
266	Dietary intake and counseling, weight maintenance, and the course of HIV infection. <i>Journal of the American Dietetic Association</i> , 1995 , 95, 428-32; quiz 433-5		61
265	Interaction between body mass index and central adiposity and risk of incident cognitive impairment and dementia: results from the Women's Health Initiative Memory Study. <i>Journal of the American Geriatrics Society</i> , 2011 , 59, 107-12	5.6	59
264	Hydrazine sulfate in cancer patients with weight loss. A placebo-controlled clinical experience. <i>Cancer</i> , 1987 , 59, 406-10	6.4	55
263	Association of Obesity-Related Metabolic Disruptions With Cancer Risk and Outcome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4249-4255	2.2	55
262	Cardiovascular Disease After Aromatase Inhibitor Use. <i>JAMA Oncology</i> , 2016 , 2, 1590-1597	13.4	54
261	Intentional Weight Loss and Endometrial Cancer Risk. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1189-1193	2.2	53
260	Association between sleep and breast cancer incidence among postmenopausal women in the Women's Health Initiative. <i>Sleep</i> , 2013 , 36, 1437-44	1.1	52
259	Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. <i>Journal of Clinical Oncology</i> , 2009 , 27, 6135-43 ²	2.2	52
258	Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 3079-85	4	51
257	Gender influence on weight-loss pattern and survival of nonsmall cell lung carcinoma patients. <i>Cancer</i> , 1996 , 78, 2119-26	6.4	51

256	Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative. <i>Gynecologic Oncology</i> , 2014 , 133, 4-10	4.9	50
255	American Society of Clinical Oncology policy statement: the role of the oncologist in cancer prevention and risk assessment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 986-93	2.2	50
254	Reducing the risk of breast cancer. <i>New England Journal of Medicine</i> , 2000 , 343, 191-8	59.2	49
253	Weight Loss Randomized Intervention Trials in Female Cancer Survivors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4238-4248	2.2	49
252	Comorbidities and mammography use interact to explain racial/ethnic disparities in breast cancer stage at diagnosis. <i>Cancer</i> , 2011 , 117, 3252-61	6.4	48
251	Vitamin K in the treatment of cancer. <i>Cancer Treatment Reviews</i> , 1985 , 12, 49-63	14.4	47
250	Diabetes, metformin use, and colorectal cancer survival in postmenopausal women. <i>Cancer Epidemiology</i> , 2013 , 37, 742-9	2.8	46
249	Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. <i>Journal of the National Cancer Institute</i> , 2008 , 100, 563-71	9.7	46
248	Metabolic Obesity Phenotypes and Risk of Breast Cancer in Postmenopausal Women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1730-1735	4	45
247	Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 375-85	4.4	45
246	Dietary glycemic load, glycemic index, and carbohydrate and risk of breast cancer in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2011 , 63, 899-907	2.8	45
245	Differences between estimated caloric requirements and self-reported caloric intake in the women's health initiative. <i>Annals of Epidemiology</i> , 2003 , 13, 629-37	6.4	45
244	Vitamin D and breast cancer: interpreting current evidence. <i>Breast Cancer Research</i> , 2011 , 13, 217	8.3	44
243	Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 1469-75	9.7	44
242	Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 275-85	4.4	43
241	Hormonal factors and risks of esophageal squamous cell carcinoma and adenocarcinoma in postmenopausal women. <i>Cancer Prevention Research</i> , 2011 , 4, 840-50	3.2	43
240	Quantifying mediating effects of endogenous estrogen and insulin in the relation between obesity, alcohol consumption, and breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 1203-12	4.2	43
239	Pathophysiology of malnutrition in the adult cancer patient. <i>Cancer</i> , 1986 , 58, 1867-1873	6.4	43

238	Body mass index, physical activity, and survival after endometrial cancer diagnosis: results from the Women's Health Initiative. <i>Gynecologic Oncology</i> , 2013 , 128, 181-6	4.9	42
237	Placebo adherence, clinical outcomes, and mortality in the women's health initiative randomized hormone therapy trials. <i>Medical Care</i> , 2011 , 49, 427-35	3.1	42
236	Cardiovascular disease and mortality after breast cancer in postmenopausal women: Results from the Women's Health Initiative. <i>PLoS ONE</i> , 2017 , 12, e0184174	3.7	42
235	Cyclophosphamide (NSC 26271) versus the combination of adriamycin (NSC 123127), 5-fluorouracil (NSC 19893), and cyclophosphamide in the treatment of metastatic prostatic cancer: a randomized trial. <i>Cancer</i> , 1978 , 42, 2546-52	6.4	41
234	Intentional Weight Loss and Obesity-Related Cancer Risk. <i>JNCI Cancer Spectrum</i> , 2019 , 3, pkz054	4.6	40
233	Quality of life in MAP.3 (Mammary Prevention 3): a randomized, placebo-controlled trial evaluating exemestane for prevention of breast cancer. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1427-36	2.2	40
232	Adherence to oral endocrine therapy for breast cancer: a nursing perspective. <i>Clinical Journal of Oncology Nursing</i> , 2008 , 12, 213-21	1.1	40
231	Metabolic abnormalities in cancer patients: carbohydrate metabolism. <i>Surgical Clinics of North America</i> , 1986 , 66, 957-68	4	40
230	Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, e181212	13.4	40
229	Statins and breast cancer stage and mortality in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2015 , 26, 529-39	2.8	39
228	Vitamin D intake and lung cancer risk in the Women's Health Initiative. <i>American Journal of Clinical Nutrition</i> , 2013 , 98, 1002-11	7	39
227	Implementing a low-fat eating plan in the Women's Intervention Nutrition Study. <i>Journal of the American Dietetic Association</i> , 2009 , 109, 688-96		39
226	Birth weight and subsequent risk of cancer. <i>Cancer Epidemiology</i> , 2014 , 38, 538-43	2.8	38
225	Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1419-1428	2.2	37
224	Weight loss and breast cancer incidence in postmenopausal women. <i>Cancer</i> , 2019 , 125, 205-212	6.4	37
223	Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. <i>Annals of Internal Medicine</i> , 2014 , 160, 594-602	8	36
222	Risk of breast, endometrial, colorectal, and renal cancers in postmenopausal women in association with a body shape index and other anthropometric measures. <i>Cancer Causes and Control</i> , 2015 , 26, 219-229	2.8	36
221	Cancer incidence and mortality during the intervention and postintervention periods of the Women's Health Initiative dietary modification trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014 , 23, 2924-35	4	36

220	A breast cancer Nutrition Adjuvant Study (NAS): protocol design and initial patient adherence. <i>Breast Cancer Research and Treatment</i> , 1987 , 10, 21-9	4.4	36
219	Aromatase inhibitors, tamoxifen, and endometrial cancer in breast cancer survivors. <i>Cancer</i> , 2015 , 121, 2147-55	6.4	35
218	SNPs and breast cancer risk prediction for African American and Hispanic women. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 583-9	4.4	35
217	Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1868-76	4	35
216	Insulin, physical activity, and caloric intake in postmenopausal women: breast cancer implications. <i>Journal of Clinical Oncology</i> , 2004 , 22, 4507-13	2.2	35
215	Critical evaluation of the role of nutritional support with chemotherapy. <i>Cancer</i> , 1985 , 55, 268-72	6.4	34
214	Hormone Use, Reproductive History, and Risk of Lung Cancer: The Women's Health Initiative Studies. <i>Journal of Thoracic Oncology</i> , 2015 , 10, 1004-13	8.9	33
213	Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. <i>International Journal of Cancer</i> , 2006 , 118, 1292-301	7.5	33
212	Adriamycin and methyl-CCNU combination therapy in hepatocellular carcinoma: clinical and pharmacokinetic aspects. <i>Cancer</i> , 1981 , 48, 1088-95	6.4	33
211	Relationships between dog ownership and physical activity in postmenopausal women. <i>Preventive Medicine</i> , 2015 , 70, 33-8	4.3	32
210	Birth weight, breast cancer and the potential mediating hormonal environment. <i>PLoS ONE</i> , 2012 , 7, e40199	3.7	32
209	Elements of informed consent for hormone replacement therapy in patients with diagnosed breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 130-42	2.2	32
208	Projecting Individualized Absolute Invasive Breast Cancer Risk in US Hispanic Women. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	31
207	IBIS-I tamoxifen update: maturity brings questions. <i>Lancet Oncology, The</i> , 2015 , 16, 7-9	21.7	31
206	Estrogen alone and joint symptoms in the Women's Health Initiative randomized trial. <i>Menopause</i> , 2013 , 20, 600-8	2.5	31
205	Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2690-7	2.2	31
204	Clinical perspectives on the utility of aromatase inhibitors for the adjuvant treatment of breast cancer. <i>Breast</i> , 2009 , 18 Suppl 2, S1-11	3.6	31
203	Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2008 , 112 Suppl 1, 25-34	4.4	31

202	Breast cancer chemoprevention. Tamoxifen: current issues and future prospective. <i>Cancer</i> , 1993 , 72, 1032-7	6.4	31
201	Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2899-905	2.2	30
200	Aromatase inhibitor-associated arthralgias. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4932-4	2.2	30
199	Diabetes, metformin and incidence of and death from invasive cancer in postmenopausal women: Results from the women's health initiative. <i>International Journal of Cancer</i> , 2016 , 138, 1915-27	7.5	30
198	Estrogen plus progestin and risk of benign proliferative breast disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008 , 17, 2337-43	4	29
197	The association between aspirin use and the incidence of colorectal cancer in women. <i>American Journal of Epidemiology</i> , 2006 , 164, 567-75	3.8	29
196	Diabetes and lung cancer among postmenopausal women. <i>Diabetes Care</i> , 2012 , 35, 1485-91	14.6	28
195	Breast cancer risk reduction: strategies for women at increased risk. <i>Annual Review of Medicine</i> , 2002 , 53, 519-40	17.4	28
194	Cardiometabolic risk factors and survival after breast cancer in the Women's Health Initiative. <i>Cancer</i> , 2018 , 124, 1798-1807	6.4	27
193	Low-fat Dietary Pattern and Pancreatic Cancer Risk in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. <i>Journal of the National Cancer Institute</i> , 2018 , 110,	9.7	27
192	Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. <i>Steroids</i> , 2014 , 90, 53-9	2.8	27
191	Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. <i>Current Medical Research and Opinion</i> , 2006 , 22, 1575-85	2.5	27
190	Sex hormone levels and risk of breast cancer with estrogen plus progestin. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 1496-503	9.7	26
189	Dosimetry and preliminary human studies of 18F-5-fluorouracil. <i>International Journal of Nuclear Medicine and Biology</i> , 1982 , 9, 25-35		26
188	Effect of depression before breast cancer diagnosis on mortality among postmenopausal women. <i>Cancer</i> , 2017 , 123, 3107-3115	6.4	25
187	Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial. <i>Clinical Lung Cancer</i> , 2016 , 17, 10-7.e1	4.9	25
186	A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. <i>Breast Cancer Research and Treatment</i> , 2009 , 116, 339-50	4.4	25
185	The scope of nutrition intervention trials with cancer-related endpoints. <i>Cancer</i> , 1994 , 74, 2734-8	6.4	25

184	Obesity and Cancer: Insights for Clinicians. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4197-4202	2.2	25
183	Menopausal hormone therapy and breast cancer mortality: clinical implications. <i>Therapeutic Advances in Drug Safety</i> , 2015 , 6, 45-56	3.5	24
182	Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results From the Women's Health Initiative. <i>Journal of Clinical Oncology</i> , 2016 , 34, 360-8	2.2	24
181	Estrogen and colorectal cancer incidence and mortality. <i>Cancer</i> , 2015 , 121, 3261-71	6.4	24
180	Regression calibration in nutritional epidemiology: example of fat density and total energy in relationship to postmenopausal breast cancer. <i>American Journal of Epidemiology</i> , 2013 , 178, 1663-72	3.8	24
179	Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 1368-78	4	24
178	Estrogen deficiency symptom management in breast cancer survivors in the changing context of menopausal hormone therapy. <i>Seminars in Oncology</i> , 2003 , 30, 776-88	5.5	24
177	Serum glucose and insulin and risk of cancers of the breast, endometrium, and ovary in postmenopausal women. <i>European Journal of Cancer Prevention</i> , 2018 , 27, 261-268	2	23
176	Adiponectin pathway polymorphisms and risk of breast cancer in African Americans and Hispanics in the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2013 , 139, 461-8	4.4	23
175	Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2019 , 174, 785-794	4.4	22
174	Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	22
173	Metformin and breast and gynecological cancer risk among women with diabetes. <i>BMJ Open Diabetes Research and Care</i> , 2015 , 3, e000049	4.5	22
172	Changing concepts of hormone receptor-positive advanced breast cancer therapy. <i>Clinical Breast Cancer</i> , 2013 , 13, 159-66	3	22
171	25-hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. <i>Maturitas</i> , 2011 , 68, 73-8	5	22
170	Association of Cataract Surgery With Mortality in Older Women: Findings from the Women's Health Initiative. <i>JAMA Ophthalmology</i> , 2018 , 136, 3-10	3.9	21
169	Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. <i>Breast Cancer Research and Treatment</i> , 2012 , 131, 969-79	4.4	21
168	Racial/ethnic differences in use and duration of adjuvant hormonal therapy for breast cancer in the women's health initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 365-73	4	21
167	Menopausal hormone therapy, hormone receptor status, and lung cancer in women. <i>Seminars in Oncology</i> , 2009 , 36, 566-71	5.5	21

166	5-fluorouracil vs. epirubicin vs. 5-fluorouracil plus epirubicin in advanced gastric carcinoma. <i>Investigational New Drugs</i> , 1994 , 12, 57-63	4.3	21
165	Racial and Ethnic Differences in Anthropometric Measures as Risk Factors for Diabetes. <i>Diabetes Care</i> , 2019 , 42, 126-133	14.6	21
164	Diabetes mellitus as a risk factor for gastrointestinal cancers among postmenopausal women. <i>Cancer Causes and Control</i> , 2013 , 24, 577-85	2.8	20
163	Menopausal hormone therapy after breast cancer. <i>Lancet, The</i> , 2004 , 363, 410-1	40	20
162	Physical activity and sedentary behavior in relation to lung cancer incidence and mortality in older women: The Women's Health Initiative. <i>International Journal of Cancer</i> , 2016 , 139, 2178-92	7.5	20
161	Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. <i>Breast Cancer Research</i> , 2014 , 16, R30	8.3	19
160	Vitamin D and calcium supplementation and one-year change in mammographic density in the women's health initiative calcium and vitamin D trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 462-73	4	19
159	National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women. <i>Clinical Breast Cancer</i> , 2007 , 7, 895-900	3	19
158	Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy: A Randomized Trial. <i>Annals of Internal Medicine</i> , 2019 , 171, 406-414	8	19
157	Variation in the FGFR2 gene and the effect of a low-fat dietary pattern on invasive breast cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 74-9	4	18
156	Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes. <i>Journal of Nutrition</i> , 2019 , 149, 1565-1574	4.1	17
155	Adjuvant endocrine therapy of perimenopausal and recently postmenopausal women with hormone receptor-positive breast cancer. <i>Clinical Breast Cancer</i> , 2014 , 14, 147-53	3	17
154	Sexual dysfunction and aromatase inhibitor use in survivors of breast cancer. <i>Clinical Breast Cancer</i> , 2009 , 9, 219-24	3	17
153	Alcohol and folate consumption and risk of benign proliferative epithelial disorders of the breast. <i>International Journal of Cancer</i> , 2007 , 121, 1346-51	7.5	17
152	Lifestyle change including dietary fat reduction and breast cancer outcome. <i>Journal of Nutrition</i> , 2007 , 137, 233S-235S	4.1	17
151	Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: prognostic aspects of the differential white blood cell count. <i>Cancer</i> , 1980 , 45, 2240-4	6.4	17
150	Serum lipids and risk of obesity-related cancers in postmenopausal women. <i>Cancer Causes and Control</i> , 2018 , 29, 13-24	2.8	17
149	Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 609-16	4.4	16

148	Reproductive and menstrual factors and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2011 , 22, 1415-24	2.8	16
147	Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women. <i>Cancers</i> , 2017 , 9,	6.6	15
146	Frequency of private spiritual activity and cardiovascular risk in postmenopausal women: the Women's Health Initiative. <i>Annals of Epidemiology</i> , 2013 , 23, 239-45	6.4	15
145	Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015 , 13, 917-24	7.3	15
144	New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. <i>Archives of Internal Medicine</i> , 2009 , 169, 1684-91		15
143	Bisphosphonates and breast cancer prevention. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012 , 12, 144-50		15
142	Dietary vitamin D and calcium intake and mammographic density in postmenopausal women. <i>Menopause</i> , 2010 , 17, 1152-60	2.5	15
141	Differential pulse polarographic determination of plasma menadione. <i>Analytical Biochemistry</i> , 1984 , 141, 488-93	3.1	15
140	Oral bisphosphonate use and risk of postmenopausal endometrial cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1186-90	2.2	14
139	Insulin resistance and breast cancer incidence and mortality in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2020 , 126, 3638-3647	6.4	14
138	New directions in the nutritional management of the cancer patient. <i>Nutrition Research</i> , 1993 , 13, 3-21	4	14
137	Online Health Information-Seeking Among Older Women With Chronic Illness: Analysis of the Women's Health Initiative. <i>Journal of Medical Internet Research</i> , 2020 , 22, e15906	7.6	14
136	Performance of the Breast Cancer Risk Assessment Tool Among Women Age 75 Years and Older. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	13
135	Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017 , 161, 185-190	4.4	13
134	Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2013 , 28, 2043-8	6.3	13
133	Low-fat dietary pattern and risk of benign proliferative breast disease: a randomized, controlled dietary modification trial. <i>Cancer Prevention Research</i> , 2008 , 1, 275-84	3.2	13
132	Insulin Resistance and Cancer-Specific and All-Cause Mortality in Postmenopausal Women: The Women's Health Initiative. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 170-178	9.7	13
131	Sex Steroid Hormones and Fracture in a Multiethnic Cohort of Women: The Women's Health Initiative Study (WHI). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 1538-1547	5.6	12

130	Menopausal estrogen therapy and non-Hodgkin's lymphoma: A post-hoc analysis of women's health initiative randomized clinical trial. <i>International Journal of Cancer</i> , 2016 , 138, 604-11	7.5	12
129	Stratified Probabilistic Bias Analysis for Body Mass Index-related Exposure Misclassification in Postmenopausal Women. <i>Epidemiology</i> , 2018 , 29, 604-613	3.1	12
128	Calcium plus vitamin D supplementation and joint symptoms in postmenopausal women in the women's health initiative randomized trial. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2013 , 113, 1302-10	3.9	12
127	Research staff turnover and participant adherence in the Women's Health Initiative. <i>Contemporary Clinical Trials</i> , 2003 , 24, 422-35		12
126	Treatment of advanced breast carcinoma with 5-fluorouracil: a randomized comparison of two routes of delivery. <i>Cancer</i> , 1981 , 48, 1711-4	6.4	12
125	Alcohol Use and Breast Cancer Survival among Participants in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1268-73	4	12
124	Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. <i>Menopause</i> , 2018 , 25, 985-991	2.5	12
123	Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative. <i>International Journal of Cancer</i> , 2017 , 141, 2281-2290	7.5	11
122	Comparison of Mortality Among Participants of Women's Health Initiative Trials With Screening-Detected Breast Cancers vs Interval Breast Cancers. <i>JAMA Network Open</i> , 2020 , 3, e207227	10.4	11
121	Factors Associated With Early Discontinuation of Study Treatment in the Mammary Prevention.3 Breast Cancer Chemoprevention Trial. <i>Journal of Clinical Oncology</i> , 2017 , 35, 629-635	2.2	10
120	36-Item Short Form Survey (SF-36) Versus Gait Speed As Predictor of Preclinical Mobility Disability in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2018 , 66, 706-713	5.6	10
119	Use of Calcium Channel Blockers and Breast Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1345-1348	4	10
118	Alcohol consumption and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2066-72	4	10
117	Hormone therapy, estrogen metabolism, and risk of breast cancer in the Women's Health Initiative Hormone Therapy Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012 , 21, 2022-32	4	10
116	Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative. <i>Cancer Causes and Control</i> , 2007 , 18, 431-8	2.8	10
115	Progestins and recurrence in breast cancer survivors. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 471-2	9.7	10
114	Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50-59 Years of Age. <i>American Journal of Epidemiology</i> , 2021 , 190, 365-375	3.8	10
113	Estrogen alone and health outcomes in black women by African ancestry: a secondary analyses of a randomized controlled trial. <i>Menopause</i> , 2017 , 24, 133-141	2.5	9

112	Cost-effectiveness analysis of a low-fat diet in the prevention of breast and ovarian cancer. <i>Journal of the American Dietetic Association</i> , 2011 , 111, 56-66		9
111	Prospective evaluation of two recruitment strategies for a randomized controlled cancer prevention trial. <i>Clinical Trials</i> , 2010 , 7, 744-8	2.2	9
110	Caution in reinterpreting the Women's Health Initiative (WHI) Calcium and Vitamin D Trial breast cancer results. <i>American Journal of Clinical Nutrition</i> , 2012 , 95, 258-9; author reply 259	7	9
109	Metabolic response to chemotherapy in colon cancer patients. <i>Journal of Parenteral and Enteral Nutrition</i> , 1992 , 16, 65S-71S	4.2	9
108	Association between Dietary Energy Density and Obesity-Associated Cancer: Results from the Women's Health Initiative. <i>Journal of the Academy of Nutrition and Dietetics</i> , 2018 , 118, 617-626	3.9	9
107	Low-Fat Dietary Pattern and Cancer Mortality in the Women's Health Initiative (WHI) Randomized Controlled Trial. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky065	4.6	9
106	Sedentary time and postmenopausal breast cancer incidence. <i>Cancer Causes and Control</i> , 2017 , 28, 1405-1416	1.8	8
105	Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model. <i>Medical Decision Making</i> , 2002 , 22, 386-93	2.5	8
104	Unpublished Data Summaries and the design and conduct of clinical trials. The Nutrition Adjuvant Study experience and commentary. <i>Contemporary Clinical Trials</i> , 1989 , 10, 368-77		8
103	Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. <i>Annals of Surgical Oncology</i> , 2020 , 27, 4687-4694	3.1	8
102	Pet Ownership and Cancer Risk in the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016 , 25, 1311-6	4	8
101	Prediagnostic Calcium Intake and Lung Cancer Survival: A Pooled Analysis of 12 Cohort Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017 , 26, 1060-1070	4	7
100	Forty-year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women. <i>Cancer</i> , 2020 , 126, 2956-2964	6.4	7
99	Post-diagnosis body mass index and mortality among women diagnosed with endometrial cancer: Results from the Women's Health Initiative. <i>PLoS ONE</i> , 2017 , 12, e0171250	3.7	7
98	Hematopoietic prostaglandin D synthase (HPGDS): a high stability, Val187Ile isoenzyme common among African Americans and its relationship to risk for colorectal cancer. <i>Prostaglandins and Other Lipid Mediators</i> , 2012 , 97, 22-8	3.7	7
97	Recreational physical activity, anthropometric factors, and risk of ductal carcinoma in situ of the breast in a cohort of postmenopausal women. <i>Cancer Causes and Control</i> , 2010 , 21, 2173-81	2.8	7
96	Altered metabolism and mortality in patients with colon cancer receiving chemotherapy. <i>American Journal of the Medical Sciences</i> , 1995 , 310, 48-55	2.2	7
95	Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. <i>Menopause</i> , 2018 , 26, 578-587	2.5	7

94	Breast Cancer Outcomes in a Racially and Ethnically Diverse Cohort of Insured Women. <i>Ethnicity and Disease</i> , 2018 , 28, 565-574	1.8	7
93	Menopausal hormone therapy and the incidence of carpal tunnel syndrome in postmenopausal women: Findings from the Women's Health Initiative. <i>PLoS ONE</i> , 2018 , 13, e0207509	3.7	7
92	Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. <i>Journal of the American Geriatrics Society</i> , 2017 , 65, 1924-1931	5.6	6
91	Interpreting quality-of-life data from the SOFT and TEXT trials. <i>Lancet Oncology, The</i> , 2015 , 16, 749-51	21.7	6
90	The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women's Health Initiative. <i>Breast Cancer Research and Treatment</i> , 2020 , 180, 747-757	4.4	6
89	Breast cancer survivorship: state of the science. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 593-604	4	6
88	Association of 25-hydroxyvitamin D levels and cutaneous melanoma: A nested case-control study of the Women's Health Initiative Observation Study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 145-147	4.5	6
87	Severity of comorbid conditions and early-stage breast cancer therapy: linked SEER-Medicare data from 1993 to 2005. <i>Cancer Medicine</i> , 2013 , 2, 526-36	4.8	6
86	Doxorubicin and CCNU with or without vincristine in patients with advanced refractory breast cancer. A randomized trial. <i>Cancer</i> , 1983 , 52, 606-9	6.4	6
85	Factors influencing the interim interpretation of a breast cancer trial: danger of achieving the "expected" result. <i>Contemporary Clinical Trials</i> , 1981 , 2, 123-32		6
84	Weight loss, diet composition and breast cancer incidence and outcome in postmenopausal women. <i>Oncotarget</i> , 2019 , 10, 3088-3092	3.3	6
83	Current concepts in breast cancer chemoprevention. <i>Polish Archives of Internal Medicine</i> , 2014 , 124, 191-9	9	6
82	Breast Cancer Prevention: Time for Change. <i>JCO Oncology Practice</i> , 2021 , 17, 709-716	2.3	6
81	Ovarian Suppression in Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 858-861	2.2	5
80	Accounting for individualized competing mortality risks in estimating postmenopausal breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2016 , 160, 547-562	4.4	5
79	Fine mapping of 14q24.1 breast cancer susceptibility locus. <i>Human Genetics</i> , 2012 , 131, 479-90	6.3	5
78	Investigating the association of lactation history and postmenopausal breast cancer risk in the Women's Health Initiative. <i>Nutrition and Cancer</i> , 2013 , 65, 969-81	2.8	5
77	Strategies to overcome endocrine therapy resistance in hormone receptor-positive advanced breast cancer. <i>Clinical Investigation</i> , 2014 , 4, 19-33		5

76	Walking speed, physical activity, and breast cancer in postmenopausal women. <i>European Journal of Cancer Prevention</i> , 2014 , 23, 49-52	2	5
75	Caution regarding 25-hydroxyvitamin D monitoring in women with breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, e72-3; author reply e74	2.2	5
74	Cardiometabolic risk factors and survival after cancer in the Women's Health Initiative. <i>Cancer</i> , 2021 , 127, 598-608	6.4	5
73	Serum 25-hydroxyvitamin D concentrations and lung cancer risk in never-smoking postmenopausal women. <i>Cancer Causes and Control</i> , 2017 , 28, 1053-1063	2.8	4
72	Dual-Outcome Intention-to-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. <i>American Journal of Epidemiology</i> , 2020 , 189, 972-981	3.8	4
71	Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls. <i>Breast Cancer Research and Treatment</i> , 2016 , 156, 567-576	4.4	4
70	Clinical trial presentations, agency guidelines, and oncology practice: findings from the arimidex, tamoxifen, alone or in combination trial. <i>Clinical Breast Cancer</i> , 2008 , 8, 343-6	3	4
69	Abnormal mammographic findings with short-interval follow-up recommendation. <i>Clinical Breast Cancer</i> , 2005 , 6, 235-9	3	4
68	Mitoxantrone use in breast cancer patients with elevated bilirubin. <i>Breast Cancer Research and Treatment</i> , 1989 , 14, 267-74	4.4	4
67	A Coala-T-Cannabis Survey Study of breast cancer patients' use of cannabis before, during, and after treatment. <i>Cancer</i> , 2021 ,	6.4	4
66	Diabetes, metformin use, and colorectal cancer survival in women: A retrospective cohort study.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e14005-e14005	2.2	4
65	The association between DXA-derived body fat measures and breast cancer risk among postmenopausal women in the Women's Health Initiative. <i>Cancer Medicine</i> , 2020 , 9, 1581-1599	4.8	4
64	Physical activity and weight gain after smoking cessation in postmenopausal women. <i>Menopause</i> , 2019 , 26, 16-23	2.5	4
63	Early breast and prostate cancer and clinical outcomes (fracture). <i>Oncology</i> , 2009 , 23, 16-20	1.8	4
62	Dietary Moderation and Deaths From Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3071-3072	2.2	3
61	Low-fat dietary pattern and global cognitive function: Exploratory analyses of the Women's Health Initiative (WHI) randomized Dietary Modification trial. <i>EClinicalMedicine</i> , 2020 , 18, 100240	11.3	3
60	Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. <i>Journal of Cancer Epidemiology</i> , 2015 , 2015, 203284	2.8	3
59	Menopausal Hormone Therapy and Health Outcomes During the Intervention and Extended Poststopping Phases of the Women's Health Initiative Randomized Trials. <i>Obstetrical and Gynecological Survey</i> , 2014 , 69, 83-85	2.4	3

58	Risks and benefits of therapy with menopausal hormones versus selective estrogen-receptor modulators in peri- and postmenopausal women at increased breast cancer risk. <i>Menopause</i> , 2008 , 15, 804-9	2.5	3
57	Low-Fat Diet and Risk of Breast Cancer Reply. <i>JAMA - Journal of the American Medical Association</i> , 2006 , 296, 278	27.4	3
56	RESPONSE: Re: Ethnicity and Breast Cancer: Factors Influencing Differences in Incidence and Outcome. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1619-1620	9.7	3
55	Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative (WHI).. <i>Journal of Clinical Oncology</i> , 2018 , 36, e13567-e13567	2.2	3
54	Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone?. <i>International Journal of Cancer</i> , 2019 , 144, 730-740	7.5	3
53	Interaction of body mass index or waist-to-hip ratio and sun exposure associated with nonmelanoma skin cancer: A prospective study from the Women's Health Initiative. <i>Cancer</i> , 2019 , 125, 1133-1142	6.4	3
52	Association of Diet Quality and Physical Activity on Obesity-Related Cancer Risk and Mortality in Black Women: Results from the Women's Health Initiative. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 591-598	4	2
51	Post-Stroke Cancer Risk among Postmenopausal Women: The Women's Health Initiative. <i>Women's Health Issues</i> , 2018 , 28, 29-34	2.6	2
50	Hormone therapy use and outcomes in the Women's Health Initiative trials--reply. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 417-8	27.4	2
49	Adjuvant aromatase inhibitor options in overweight and obese postmenopausal women with breast cancer. <i>Breast Journal</i> , 2013 , 19, 552-4	1.2	2
48	Influence of nutritional status on circulatory ribonuclease C levels in patients with cancer. <i>Cancer</i> , 1985 , 55, 427-31	6.4	2
47	Protein Intake by Source and Breast Cancer Incidence and Mortality: The Women's Health Initiative. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa101	4.6	2
46	Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?. <i>Breast Journal</i> , 2020 , 26, 2199-2202	1.2	2
45	Low-fat dietary pattern and breast cancer mortality by metabolic syndrome components: a secondary analysis of the Women's Health Initiative (WHI) randomised trial. <i>British Journal of Cancer</i> , 2021 , 125, 372-379	8.7	2
44	Notice of Retraction and Replacement. Tseng et al. Association of cataract surgery with mortality in older women: findings from the Women's Health Initiative. <i>JAMA Ophthalmology</i> . 2018;136(1):3-10. <i>JAMA Ophthalmology</i> , 2018 , 136, 1313-1314	3.9	2
43	Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative. <i>Cancer</i> , 2021 , 127, 3742-3750	6.4	2
42	Postmenopausal Fracture History and Survival After Reproductive Cancer Diagnosis. <i>JNCI Cancer Spectrum</i> , 2018 , 2, pky001	4.6	1
41	Impact of hormone therapy on Medicare spending in the Women's Health Initiative randomized clinical trials. <i>American Heart Journal</i> , 2018 , 198, 108-114	4.9	1

40	Reply to S. Gandini et al. <i>Journal of Clinical Oncology</i> , 2013 , 31, 974-5	2.2	1
39	Lung cancer and hormone replacement therapy [Authors' reply. <i>Lancet, The</i> , 2010 , 375, 118-119	4.0	1
38	HT and breast cancer risk. <i>Sexuality, Reproduction & Menopause</i> , 2003 , 1, 15-18		1
37	Low-fat dietary pattern and breast cancer mortality by metabolic syndrome degree: Secondary analyses of the Women's Health Initiative (WHI) Dietary Modification randomized trial.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1539-1539	2.2	1
36	Postmenopausal Breast Cancer and Physical Function Change: A Difference-in-Differences Analysis. <i>Journal of the American Geriatrics Society</i> , 2020 , 68, 1029-1036	5.6	1
35	Nutritional epidemiology and the Women's Health Initiative: a review. <i>American Journal of Clinical Nutrition</i> , 2021 , 113, 1083-1092	7	1
34	Adiposity, history of diabetes, and risk of pancreatic cancer in postmenopausal women. <i>Annals of Epidemiology</i> , 2019 , 29, 23-29.e1	6.4	1
33	Breast Cancer Prevention and Breast Cancer Mortality.. <i>JCO Oncology Practice</i> , 2022 , OP2200091	2.3	1
32	Cardiovascular Outcomes in Relation to Antihypertensive Medication Use in Women with and Without Cancer: Results from the Women's Health Initiative. <i>Oncologist</i> , 2020 , 25, 712-721	5.7	0
31	Trajectory of recurrent falls in post-menopausal breast cancer survivors and in matched cancer-free controls. <i>Breast Cancer Research and Treatment</i> , 2020 , 180, 767-775	4.4	0
30	Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors. <i>Breast Journal</i> , 2012 , 18, 299-302	1.2	0
29	Cardiometabolic risk factors, physical activity, and postmenopausal breast cancer mortality: results from the Women's Health Initiative.. <i>BMC Women's Health</i> , 2022 , 22, 32	2.9	0
28	Low-Fat Dietary Modification and Risk of Ductal Carcinoma of the Breast in the Women's Health Initiative Dietary Modification Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1753-1756 ⁴		0
27	A Randomized Trial of Calcium Plus Vitamin D Supplementation and Risk of Ductal Carcinoma In Situ of the Breast. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab072	4.6	0
26	Metabolic syndrome risk components and mortality after triple-negative breast cancer diagnosis in postmenopausal women in the Women's Health Initiative. <i>Cancer</i> , 2021 , 127, 1658-1667	6.4	0
25	Sleep medication use and risk of fractures in breast cancer survivors. <i>Breast Cancer Research and Treatment</i> , 2021 , 190, 541-548	4.4	0
24	Response. <i>Breast Cancer Research and Treatment</i> , 2017 , 163, 633-634	4.4	
23	Reply to F. Conforti et al. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1840-1841	2.2	

22	Prentice et al. Respond to "Studying Co-Occurrence of Multiple Outcomes". <i>American Journal of Epidemiology</i> , 2020 , 189, 985-986	3.8
21	Emerging combination endocrine therapies for advanced breast cancer. <i>Breast Journal</i> , 2018 , 24, 214-215.	2
20	Lifestyle and Breast Cancer 2017 , 831-839	
19	Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply. <i>JAMA Oncology</i> , 2015 , 1, 1171	13.4
18	Reply to P. Niravath et Al. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3780-1	2.2
17	Clinical Perspective: Influence of Modifiable Lifestyle Factors, Body Weight, Physical Activity, and Alcohol on Breast Cancer Outcome. <i>Current Breast Cancer Reports</i> , 2012 , 4, 188-198	0.8
16	Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013 , 39, 226-8	
15	Bisphosphonates for breast cancer therapy and prevention?. <i>IBMS BoneKEy</i> , 2010 , 7, 364-368	
14	Breast Cancer in Postmenopausal Women After Hormone TherapyReply. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 305, 466	27.4
13	Hormone therapy suspension and mammography in Women's Health Initiative clinical trials. <i>Annals of Internal Medicine</i> , 2010 , 152, 133	8
12	Colorectal Cancer in Women After Stopping Postmenopausal Hormone TherapyReply. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 299, 2744	27.4
11	Trends in Prostate and Breast Cancer Clinical Research as Reported in the American Society of Clinical Oncology Proceedings. <i>Prostate Journal</i> , 2001 , 3, 26-29	
10	Tamoxifen for treatment of premenopausal women with breast cancer. <i>Cancer Investigation</i> , 2000 , 18, 681-4	2.1
9	Trajectory of recurrent falls in postmenopausal breast cancer survivors and matched cancer-free controls.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22100-e22100	2.2
8	A comprehensive evaluation of breast cancer treatment delays by race among Women's Health Initiative participants.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e18579-e18579	2.2
7	Low-fat dietary pattern and all cancer mortality in the Women's Health Initiative (WHI) randomized trial.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1500-1500	2.2
6	Racial/ethnic variations in lung cancer incidence and mortality, adjusted for smoking behavior: Results from the Women's Health Initiative.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1528-1528	2.2
5	Risk of Breast Cancer Associated with Estrogen DNA Adduct Biomarker. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 2096-2099	4

4	Genetic Predictors of Circulating 25-Hydroxyvitamin D and Prognosis after Colorectal Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1128-1134	4
3	Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data. <i>Cancer</i> , 2021 , 127, 813-814	6.4
2	Complexity of intermittent letrozole adjuvant therapy. <i>Lancet Oncology, The</i> , 2018 , 19, 13-15	21.7
1	Reply to the siren's song of anonymous web-based sampling.. <i>Cancer</i> , 2022 ,	6.4